Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

April 22, 2020April 22, 2020

Researchers Like Results of Using Nanoparticles to Carry Adapalene in ALS Mice

News

Injecting tiny particles carrying adapalene — an activator of the retinoic acid signaling pathway — to the brain and spinal cord of mice with amyotrophic lateral sclerosis (ALS) can ... Read more

April 15, 2020April 16, 2020

Shift in Immune Cells’ Balance Linked to ALS Severity and Progression, Study Finds

News

A shift in the make-up of immune cells found in the blood of patients with amyotrophic lateral sclerosis (ALS) favors specific types of pro-inflammatory T-helper cells in detriment to ... Read more

April 7, 2020April 7, 2020

Discovery of Link Between Cellular Hallmarks of ALS May Lead to New Therapies

News

By blocking the activity of the proteasome — a complex of enzymes responsible for the destruction of unnecessary or damaged proteins — dipeptide repeat (DPR) proteins associated with C9ORF72 gene ... Read more

January 21, 2020January 21, 2020

Masitinib Alleviates Inflammatory Response Triggered by Schwann Cells in Rat Model of ALS

News

A recently discovered inflammatory mechanism triggered by Schwann cells — specialized cells that produce the protective myelin sheath around neurons — in amyotrophic lateral sclerosis (ALS) can be alleviated with ... Read more

November 14, 2019November 14, 2019

Blocking SARM1 Prevents Neuronal Degeneration in Mice and Cell Models, Study Shows

News

Small molecule inhibitors that block the activity of SARM1 — an enzyme that plays a key role in nerve cell degeneration — prevent the degeneration of axons in mice ... Read more

October 23, 2019October 23, 2019

Protein Related to ALS Onset Used to Develop New Method of Antibody Validation for Use in Research

News

Scientists have developed a new method to validate antibodies for research, demonstrating its effectiveness by using the protein encoded by the C9ORF72 gene, which, when mutated, may cause amyotrophic ... Read more

October 17, 2019October 17, 2019

First ALS Patient Enrolled in Phase 1 Trial of AP-101, AL-S Pharma AG Announces

News

AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, has enrolled the first patient in its Phase 1 clinical trial assessing ... Read more

October 16, 2019October 16, 2019

First ALS Patient Enrolled in Phase 2/3 Trial of CuATSM, CMD Announces

News

Collaborative Medicinal Development (CMD) has enrolled the first patient in its Phase 2/3 clinical trial assessing the safety and efficacy of CuATSM, an investigational therapy for amyotrophic lateral sclerosis ... Read more

October 8, 2019October 8, 2019

Reldesemtiv Slows Decline in Muscle Control Needed for Speech, Phase 2 Trial Analysis Finds

News

Use of reldesemtiv in a clinical trial in amyotrophic lateral sclerosis (ALS) patients led to a slower decline in muscle control needed for speech relative to placebo, a study reports. The ... Read more

October 4, 2019October 4, 2019

U.S. Department of Defense Earmarks $758,121 to Develop RASRx1902 as Potential ALS Therapy

News

The U.S. Department of Defense (DoD) has issued a two-year research grant totaling $758,121 to support a group of scientists from the University of Arizona Health Sciences Center for Innovation ... Read more

Pin It on Pinterest